Effect of a New Preservative-free Combination of Trehalose, Sodium Hyaluronate and N-acetyl-aspartyl-glutamate (NAAGA) on Dry Eye Disease and Patient Quality of Life
Effect of a New Preservative-free Combination of Trehalose, Sodium Hyaluronate and N-acetyl-aspartyl-glutamate (NAAGA) on Dry Eye Disease and Patient Quality of Life
The goal of this prospective, non-randomized, non-comparative, monocentric PMCF study is to assess the performance of a new preservative-free combination of trehalose, sodium hyaluronate and NAAGA on DED at 6 months in 30 patients having dry eye disease.
The main questions it aims to answer are:
Inclusion Criteria:
Exclusion Criteria:
Ophthalmic Exclusion Criteria in at least one eye •Far BCVA ≥+0.7 LogMAR (e.g., ≤0.2 in decimal value or ≤20/100 Snellen equivalent or ≤50 ETDRS letters).
Systemic/non Ophthalmic Exclusion Criteria
Specific Exclusion Criteria Regarding Childbearing Potential Women
Exclusion Criteria Related to General Conditions
Exclusion criteria related to previous and concomitant treatments (medications/non-medicinal therapies/procedures)
•Participant with previous, current or anticipated prohibited listed treatment (or prohibited modification of treatment regimen).